XML 38 R28.htm IDEA: XBRL DOCUMENT v3.23.4
Business Combination (Tables)
9 Months Ended
Sep. 30, 2023
Business Combination  
summary the preliminary estimated fair value

Description

 

Fair Value as of January 9, 2023

 

Fair value of 14,649.591 Series X Convertible Preferred Stock issued

 

$69,140

 

Fair value of Old Catheter's fully vested stock options

 

 

3,404

 

Total purchase price

 

$72,544

 

summary Of preliminary purchase price allocations

Description

 

Fair Value

 

Assets acquired:

 

 

 

Cash and cash equivalents

 

$15

 

Accounts receivable

 

 

71

 

Inventories

 

 

52

 

Prepaid expenses and other current assets

 

 

23

 

Property and equipment, net

 

 

26

 

Lease right-of-use assets

 

 

119

 

Other assets

 

 

8

 

Developed technology

 

 

27,014

 

Customer relationships

 

 

62

 

Trademarks

 

 

1,285

 

Goodwill

 

 

60,934

 

Total assets acquired

 

 

89,609

 

 

 

 

 

 

Liabilities assumed:

 

 

 

 

Accounts payable

 

$922

 

Accrued expense

 

 

1,389

 

Interest payable

 

 

198

 

Convertible promissory note

 

 

250

 

Lease liability

 

 

124

 

Royalties payable

 

 

14,182

 

Total liabilities assumed

 

 

17,065

 

Total purchase price

 

$72,544

 

Schedule of acquisition date fair values and estimated useful lives

Intangible Assets

 

Estimated Fair

Value

 

 

Estimated Useful Life

in Years

 

Developed technology - VIVO

 

$8,244

 

 

 

15

 

Developed technology - LockeT

 

 

18,770

 

 

 

14

 

Customer relationships

 

 

62

 

 

 

6

 

Trademark - VIVO

 

 

876

 

 

 

9

 

Trademark - LockeT

 

 

409

 

 

 

9

 

 

 

$28,361

 

 

 

 

 

Schedule of Basic and diluted net loss per share - on a pro forma basis

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

 

September 30,

 

 

September 30,

 

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Revenues

 

$133

 

 

$60

 

 

$317

 

 

$206

 

Net loss

 

 

(1,927)

 

 

(6,295)

 

 

(70,073)

 

 

(23,167)

Net loss attributable to common stockholders

 

 

(1,927)

 

 

(6,295)

 

 

(70,873)

 

 

(23,167)

Basic and diluted net loss per share - on a pro forma basis (unaudited)

 

$(0.28)

 

$(5.76)

 

$(14.07)

 

$(34.66)